A
FBRX icon

AlphaQuest’s Forte Biosciences FBRX Stock Holding History

AlphaQuest’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,804
Closed -$513K – 714
2025
Q4 		$513K Buy
18,804
+6,513
+53% +$114K 0.03% 807
2025
Q3 		$184K Sell
12,291
-4,606
-27% -$53.1K 0.01% 1449
2025
Q2 		$218K Buy
16,897
+12,680
+301% +$109K 0.02% 1072
2025
Q1 		$32.7K Buy
+4,217
New +$49.8K ﹤0.01% 1622

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

AlphaQuest's FBRX Position: Q1 2026 in Review

AlphaQuest sold out of Forte Biosciences (FBRX) in Q1 2026, closing a stake of 18,804 shares — an estimated $513K sold.

AlphaQuest first reported a position in FBRX in Q1 2025 and held it in 4 quarters. The position peaked at $513K in Q4 2025. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • AlphaQuest reported no remaining Forte Biosciences position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 18,804 Forte Biosciences shares in Q1 2026, an estimated $513K.
  • AlphaQuest first reported a position in Forte Biosciences in Q1 2025 and held it in 4 quarters.
  • AlphaQuest's Forte Biosciences position peaked at $513K in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.